modelRopinirole
Extends from Pharmacolibrary.Drugs.ATC.N.N04BC04.
Information
| name: | Ropinirole | |
| ATC code: | N04BC04 | route: | oral |
| compartments: | 1 | |
| dosage: | 2 | mg |
| volume of distribution: | 7.5 | L |
| clearance: | 3.36 | L/h/kg |
| other parameters in model implementation | ||
Ropinirole is a non-ergoline dopamine agonist primarily used in the treatment of Parkinson's disease and restless legs syndrome. It is approved for clinical use in many countries, including the USA and Europe, for both indications.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult male and female volunteers after single oral administration.
References
Kaye, CM, & Nicholls, B (2000). Clinical pharmacokinetics of ropinirole. Clinical pharmacokinetics 39(4) 243–254. DOI:10.2165/00003088-200039040-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11069211
Hattori, N, et al., & Sakamoto, T (2012). Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease. Journal of clinical pharmacy and therapeutics 37(5) 571–577. DOI:10.1111/j.1365-2710.2012.01336.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22390368
Lai, KL, et al., & Lee, WYT (2018). Orally-dissolving film for sublingual and buccal delivery of ropinirole. Colloids and surfaces. B, Biointerfaces 163 9–18. DOI:10.1016/j.colsurfb.2017.12.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29268211
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)